Maynard Um
-
-
-
-
-
-
-
Praxis pauses vormatrigine study after trial misses primary endpoint
-
-
-
-
-
-
-
BTIG on Praxis Precision Medicines Inc. (PRAX): NDA acceptance offers clean regulatory setup for approval
-
-
-
-
-
-
-
BTIG Reiterates Buy Rating on Praxis Precision Medicines Inc. (PRAX): "see the X-TOLE2 readout as having no readthrough"
-
-
-
-
-
-
-
Praxis Precision Medicines Inc. (PRAX) PT Raised to $1,200 at Piper Sandler on 'Major Upside Potential'
-
-
-
-
-
-
-
TD Cowen Reiterates Buy Rating on Praxis Precision Medicines Inc. (PRAX)
-
-
-
-
-
-
-
Praxis Precision Medicines Inc. (PRAX) PT Raised to $843 (from $507) at BTIG
-
-
-
-
-
-
-
Praxis Precision Medicines Inc. (PRAX) PT Raised to $315 at Needham
-
404,872 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

